Logo image of AVXL

ANAVEX LIFE SCIENCES CORP (AVXL) Stock Price, Quote, News and Overview

NASDAQ:AVXL - Nasdaq - US0327973006 - Common Stock - Currency: USD

10.57  +1.24 (+13.29%)

After market: 10.55 -0.02 (-0.19%)

AVXL Quote, Performance and Key Statistics

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (7/2/2025, 6:53:02 PM)

After market: 10.55 -0.02 (-0.19%)

10.57

+1.24 (+13.29%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High14.44
52 Week Low4.24
Market Cap902.36M
Shares85.37M
Float82.56M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE7.47
Earnings (Next)08-04 2025-08-04/bmo
IPO04-13 2006-04-13


AVXL short term performance overview.The bars show the price performance of AVXL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

AVXL long term performance overview.The bars show the price performance of AVXL in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of AVXL is 10.57 USD. In the past month the price increased by 34.82%. In the past year, price increased by 152.27%.

ANAVEX LIFE SCIENCES CORP / AVXL Daily stock chart

AVXL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.57 336.94B
AMGN AMGEN INC 14.3 159.62B
GILD GILEAD SCIENCES INC 14.41 138.71B
VRTX VERTEX PHARMACEUTICALS INC N/A 117.37B
REGN REGENERON PHARMACEUTICALS 12.36 59.14B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 43.00B
ARGX ARGENX SE - ADR 94.8 33.28B
ONC BEONE MEDICINES LTD-ADR 6.23 26.43B
BNTX BIONTECH SE-ADR N/A 26.02B
NTRA NATERA INC N/A 22.06B
BIIB BIOGEN INC 8.42 19.52B
INSM INSMED INC N/A 17.89B

About AVXL

Company Profile

AVXL logo image Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 42 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. The company has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.

Company Info

ANAVEX LIFE SCIENCES CORP

630 5Th Avenue, 20Th Floor

New York City NEW YORK 10019 US

CEO: Christopher Missling

Employees: 42

AVXL Company Website

AVXL Investor Relations

Phone: 18446893939

ANAVEX LIFE SCIENCES CORP / AVXL FAQ

What is the stock price of ANAVEX LIFE SCIENCES CORP today?

The current stock price of AVXL is 10.57 USD. The price increased by 13.29% in the last trading session.


What is the ticker symbol for ANAVEX LIFE SCIENCES CORP stock?

The exchange symbol of ANAVEX LIFE SCIENCES CORP is AVXL and it is listed on the Nasdaq exchange.


On which exchange is AVXL stock listed?

AVXL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ANAVEX LIFE SCIENCES CORP stock?

9 analysts have analysed AVXL and the average price target is 43.82 USD. This implies a price increase of 314.59% is expected in the next year compared to the current price of 10.57. Check the ANAVEX LIFE SCIENCES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ANAVEX LIFE SCIENCES CORP worth?

ANAVEX LIFE SCIENCES CORP (AVXL) has a market capitalization of 902.36M USD. This makes AVXL a Small Cap stock.


How many employees does ANAVEX LIFE SCIENCES CORP have?

ANAVEX LIFE SCIENCES CORP (AVXL) currently has 42 employees.


What are the support and resistance levels for ANAVEX LIFE SCIENCES CORP (AVXL) stock?

ANAVEX LIFE SCIENCES CORP (AVXL) has a support level at 8.63 and a resistance level at 9.49. Check the full technical report for a detailed analysis of AVXL support and resistance levels.


Should I buy ANAVEX LIFE SCIENCES CORP (AVXL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ANAVEX LIFE SCIENCES CORP (AVXL) stock pay dividends?

AVXL does not pay a dividend.


When does ANAVEX LIFE SCIENCES CORP (AVXL) report earnings?

ANAVEX LIFE SCIENCES CORP (AVXL) will report earnings on 2025-08-04, before the market open.


What is the Price/Earnings (PE) ratio of ANAVEX LIFE SCIENCES CORP (AVXL)?

ANAVEX LIFE SCIENCES CORP (AVXL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.55).


What is the Short Interest ratio of ANAVEX LIFE SCIENCES CORP (AVXL) stock?

The outstanding short interest for ANAVEX LIFE SCIENCES CORP (AVXL) is 30.54% of its float. Check the ownership tab for more information on the AVXL short interest.


AVXL Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to AVXL. When comparing the yearly performance of all stocks, AVXL is one of the better performing stocks in the market, outperforming 96.12% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AVXL Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AVXL. While AVXL has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AVXL Financial Highlights

Over the last trailing twelve months AVXL reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -10% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -40.24%
ROE -47.26%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
EPS 1Y (TTM)-10%
Revenue 1Y (TTM)N/A

AVXL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to AVXL. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners37.6%
Ins Owners3.29%
Short Float %30.54%
Short Ratio28.92
Analysts
Analysts82.22
Price Target43.82 (314.57%)
EPS Next Y-13.12%
Revenue Next YearN/A